Xeris Pharmaceuticals (NSDQ:XERS) announced today that it entered into an exclusive agreement with Tetris Pharma to commercialize Ogluo. Chicago-based Xeris designed Ogluo (Gvoke PFS and Gvoke HypoPen in the U.S.) to be a ready-to-use, pre-mixed, pre-measured glucagon injection for treating severe hypoglycemia in adults, adolescents and children two years of age and older with diabetes […]
Diabetes
FDA approves Nevro spinal cord stimulation to treat chronic pain with diabetic neuropathy
Nevro (NYSE:NVRO) announced today that it received FDA approval for its Senza system for treating chronic pain associated with PDN. Redwood City, Calif.-based Nevro’s Senza system’s approval is specific to Nevro’s 10 kHz stimulation, with the company touting that it now has the only spinal cord stimulation system approved by the FDA with a specific indication […]
Dexcom CEO Kevin Sayer says G7 will be ‘wonderful’
As we enter what may be the “new normal,” Dexcom’s CEO bets the company can pave the way in continuous glucose monitoring. Dexcom (NSDQ:DXCM), like any company seeking to innovate, remains in a state of perpetual forward motion. That’s the way chair, president & CEO Kevin Sayer views it, anyway. As the company looks toward […]
FDA clears Dexcom Partner Web APIs
Dexcom (NSDQ:DXCM) announced today that it received FDA clearance for its Dexcom Partner Web application programming interfaces (APIs). The San Diego-based company’s Dexcom Partner Web APIs enable invited third-party developers to integrate real-time continuous glucose monitoring (CGM) data into their digital health apps and devices. Dexcom’s CGM data can be integrated into third-party apps and […]
Eli Lilly acquires glucose-sensing insulin developer Protomer Technologies
Eli Lilly (NYSE:LLY) announced today that it acquired peptide- and protein-engineering platform developer Protomer Technologies. Pasadena, Calif.-based Protomer Technologies develops next-generation protein therapeutics designed to identify and synthesize molecules that can sense glucose or other endogenous modulators of protein activity. Indianapolis-based Eli Lilly said in a news release that the potential value of the transaction […]
Glytec appoints chief medical officer
Cloud-based insulin management software developer Glytec announced today that it appointed Dr. Jordan Messler as chief medical officer. Messler’s responsibilities as the company’s CMO include spearheading continuous improvement initiatives for Glytec’s clinical strategy and product development. Additionally, Messler will be supporting the delivery, customer, quality and regulatory teams to ensure ethical and safe glycemic management […]
BD announces two new directors for diabetes spinoff
BD (NYSE:BDX) announced today that it appointed David F. Melcher and Dr. Claire Pomeroy as directors of its diabetes spinoff. Franklin Lakes, N.J.-based BD previously announced the separation of its diabetes care business into an independent, publicly traded company called NewCo. According to a news release, the appointments of Melcher as non-executive chair of the […]
DarioHealth touts data for diabetes management platform
DarioHealth (NSDQ:DRIO) recently presented data supporting its artificial intelligence (AI)-powered diabetes management platform. New York-based Dario’s research examined users who were given access to a new product experience designed to drive better health habits and behaviors through its AI-driven personalization engine. According to a news release, results —presented at the American Diabetes Association (ADA) 81st […]
Nominations open for the Leonard Award celebrating 100 years of insulin
Eli Lilly and Company (NYSE:LLY) is looking for nominations for its inaugural Leonard Award, which highlights advances in diabetes management. The company will select five winners and donate $100,00 to the non-profit Life for a Child, which provides medicines and supplies to children and youth with type 1 diabetes in developing countries. Lilly is launching the […]
Walmart teams up with Novo Nordisk to launch private-brand analog insulin
Walmart (NYSE:WMT) is launching what it describes as the first private label analog insulin. The company estimates the insulin products will save customers between 58% and 70% of the cost of branded insulin. Novo Nordisk (NYSE:NVO) will manufacture the analog insulin, which is a type of lab-grown insulin genetically engineered to optimize glucose control. The […]
